1 / 16

R&D Pharmaceutical Companies Partnerships to Improve Developing World Health

Explore the pharmaceutical industry's R&D efforts for diseases of the developing world, access programs, partnerships, and challenges. Learn about the industry's commitment to tackling DDW and benefiting patients in developing nations. Discover how industry efforts, partnerships, and technology transfer are shaping global health. Presented by Mario Ottiglio, Associate Director of Public Affairs & Global Health Policy at ICIUM 2011. Join the conversation on industry innovation, healthcare access, and corporate governance.

maryam-sampson
Download Presentation

R&D Pharmaceutical Companies Partnerships to Improve Developing World Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. R&D Pharmaceutical Companies Partnerships to Improve Developing World Health Mario Ottiglio Associate Director, Public Affairs & Global Health Policy ICIUM 2011, Antalya, Turkey, 15 November 2011

  2. Outline Industry’s efforts in R&D for diseases of the developing world (DDW) Industry’s access programmes Focus: Challenges in R&D Conclusive remarks

  3. Tackling DDW a combined effort to benefit patients in developing countries

  4. Overall Industry Efforts in R&D for DDW Independent Efforts Industry Dedicated DDW R&D Centers Partnerships (Current industry involvement & partnerships - illustrative only - not comprehensive)

  5. Industry DDW R&D • R&D for TDR 10 Priority Diseases: • ChagasDengueHuman African TrypanosomiasisLeishmaniasisLeprosyLymphatic FilariasisMalariaOnchocerciasisSchistosomiasisTuberculosis *1 project = 1 compound in development or 1 screening program for 1 disease

  6. DDW R&D is increasingly collaborative

  7. Industry R&D for DDW is Growing

  8. Technology Transfer Happens

  9. Industry Access Partnerships

  10. Program Types Access(32 % of all programs) Capacity Building(57 % of all programs) Education(30 % of all programs) R & D (25 % of all programs)

  11. Programs by Disease Area

  12. Largest Beneficiary in Each Region

  13. Things Have Changed...

  14. …But Challenges Remain

  15. Messages to take home • Industry’s role and unique speciality is in innovation: researching and developing drugs • As part of the solution, industry is also committed to increased access to healthcare and to maintain good corporate governance • Market failures are a reality: new complementary approaches such as Partnership are needed • Industry is ready to be engaged in constructive and inclusive dialogues • Access partnerships & drug donation programmes have raised the profile of the diseases, kick-started national diseases control programmes and improved delivery systems • The complexity of the issues is beyond the capability of any single organization or country alone

  16. Thank You! Ch. Louis-Dunant 15P.O. Box 195121211 Geneva 20Switzerland Tel: +41-22-338 32 00Fax: +41-22-338 32 99Email: info@ifpma.orgWeb: www.ifpma.org

More Related